Using murine knockout models for GPER, it has been shown that its overexpression and its location in the plasma membrane are important events for breast cancer progression (87), while the absence of GPER in the plasma membrane has an excellent long-term prognosis in patients with ERalpha + breast cancer treated with tamoxifen (88, 89). Here, ESR1 is linked to breast carcinoma.